FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2421-2422 June 7, 2007 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Shrestha, M. P. PubMed Citation

To the Editor: The study by Shrestha et al. (March 1 issue),¹ which evaluated a vaccine for hepatitis E virus (HEV), represents a major advance but continues to raise ethical concerns. The trial of the HEV recombinant protein (rHEV) vaccine, conducted by the U.S. military and GlaxoSmithKline, was forced out of a Nepalese community after protests about whether residents would have access to the vaccine after the trial.² The study was subsequently relocated to the Nepalese Army. The consent of soldiers may be "unduly influenced . . . by fear of disapproval or retaliation if they refuse,"³ which is why research involving . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.